Tumor Biology

, Volume 35, Issue 2, pp 1129–1137 | Cite as

Association of polymorphisms in interleukin-18 and interleukin-28B genes with outcomes of hepatitis B virus infections: a meta-analysis

  • Pu Xia
  • Mo Zhou
  • Dao Song Dong
  • Ya-Nan Xing
  • Yang Bai
Research Article


Several polymorphisms in the interleukin-18 (IL-18) and nterleukin-28B (IL-28B) genes have been reported to influence hepatitis B virus (HBV) infection. However, the published findings have been conflicting. We conducted meta-analyses of randomized, controlled trials to address the association of IL-18 or IL-28B polymorphisms and the outcomes of HBV infection. Weipu, Wanfang, CNKI, MEDLINE, PubMed, EMBASE, and Cochrane Library databases were employed to search for citations using the MeSH terms as “interleukin-18”/“interleukin-28B” AND “HBV” AND “gene” AND “polymorphism” without any restriction in language and publication year. Meta-analysis was conducted by RevMan 5.0 software. The results showed that the IL28B rs8099917 AA genotype (AA vs AC + CC: odds ratio (OR) = 0.63, 95 % confidence interval (CI) = 0.46–0.87) was associated with a decreased risk of hepatocellular carcinoma (HCC). Carriage of IL28B rs12979860 CC genotype was associated with an increased risk for developing liver cirrhosis among patients with HBV infection (CC vs CT + TT: OR = 1.39, 95 % CI = 1.04–1.85). Further well-designed large studies are warranted to confirm the mechanisms by which these are involved in these outcomes of HBV infection.


Meta-analysis HBV IL-18 IL-28B Polymorphisms 



The authors appreciate the thoughtful advice of Wei Wang (China Medical University).

Conflicts of interest



  1. 1.
    Maddrey WC. Hepatitis B: an important public health issue. J Med Virol. 2000;61:362–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Lee WM. Hepatitis B, virus infection. N Engl J Med. 1997;337:1733–45.PubMedCrossRefGoogle Scholar
  3. 3.
    Chen CJ, Wang LY, Yu MW. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol. 2000;15:E3–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis. 2002;2:479–86.PubMedCrossRefGoogle Scholar
  5. 5.
    Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Sem Liver Dis. 1991;11:84–92.CrossRefGoogle Scholar
  6. 6.
    Lavanchy D. Hepatitis B, virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107.PubMedCrossRefGoogle Scholar
  7. 7.
    McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49:S45–55.PubMedCrossRefGoogle Scholar
  8. 8.
    Liu YZ, Hou FQ, Ding P, Ren YY, Li SH, Wang GQ. Pegylated interferon α enhances recovery of memory T cells in e antigen positive chronic hepatitis B patients. Virol J. 2012;9:274.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Chen L, Liu WQ, Lei JH, Guan F, Li MJ, Song WJ, et al. Chronic Schistosoma japonicum infection reduces immune response to vaccine against hepatitis B in mice. PLoS One. 2012;7:e51512.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Ben-Ari Z, Mor E, Papo O, Kfir B, Sulkes J, Tambur AR, et al. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol. 2003;98:144–50.PubMedCrossRefGoogle Scholar
  11. 11.
    Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.PubMedCrossRefGoogle Scholar
  12. 12.
    Balagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis C virus infection. Gastroenterology. 2010;139:1865–76.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Li W, Jiang Y, Jin Q, Shi X, Jin J, Gao Y, et al. Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver Int. 2011;31:1118–26.PubMedCrossRefGoogle Scholar
  14. 14.
    Peng LJ, Guo JS, Zhang Z, Shi H, Wang J, Wang JY. IL28B rs12979860 polymorphism does not influence outcomes of hepatitis B virus infection. Tissue Antigens. 2012;79:302–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV. Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol. 2002;76:10702–7.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Tanaka-Kataoka M, Kunikata T, Takayama S, Iwaki K, Ohashi K, Ikeda M, et al. In vivo antiviral effect of interleukin 18 in a mouse model of vaccinia virus infection. Cytokine. 1999;11:593–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Sun Y, Chen HY, Xin SJ. Effect of IL-18 on peripheral blood mononuclear cells of chronic hepatitis B and hepatitis B virus DNA released by HepG2.2.15 cell lines. Hepatobiliary Pancreat Dis Int. 2004;3:230–4.PubMedGoogle Scholar
  18. 18.
    Kim YS, Cheong JY, Cho SW, Lee KM, Hwang JC, Oh B, et al. A functional SNP of the Interleukin-18 gene is associated with the presence of hepatocellular carcinoma in hepatitis B virus-infected patients. Dig Dis Sci. 2009;54:2722–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Higa S, Hirano T, Mayumi M, Hiraoka M, Ohshima Y, Nambu M, et al. Association between interleukin-18 gene polymorphism 105A/C and asthma. Clin Exp Allergy. 2003;33:1097–102.PubMedCrossRefGoogle Scholar
  20. 20.
    Giedraitis V, He B, Huang WX, Hillert J. Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol. 2001;112:146–52.PubMedCrossRefGoogle Scholar
  21. 21.
    Khripko OP, Sennikova NS, Lopatnikova JA, Khripko JI, Filipenko ML, Khrapov EA, et al. Association of single nucleotide polymorphisms in the IL-18 gene with production of IL-18 protein by mononuclear cells from healthy donors. Mediators Inflamm. 2008;309721.Google Scholar
  22. 22.
    Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.PubMedCrossRefGoogle Scholar
  23. 23.
    Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005;28:123–37.PubMedCrossRefGoogle Scholar
  24. 24.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in metaanalyses. BMJ. 2003;327:557–60.PubMedCrossRefGoogle Scholar
  25. 25.
    Pereira TV, Rudnicki M, Cheung BM, Baum L, Yamada Y, Oliveira PS, et al. Three endothelial nitric oxide (NOS3) gene polymorphisms in hypertensive and normotensive individuals: meta-analysis of 53 studies reveals evidence of publication bias. J Hypertens. 2007;25:1763–74.PubMedCrossRefGoogle Scholar
  26. 26.
    Hirankarn N, Manonom C, Tangkijvanich P, Poovorawan Y. Association of interleukin-18 gene polymorphism (–607A/A genotype) with susceptibility to chronic hepatitis B virus infection. Tissue Antigens. 2007;70:160–3.PubMedCrossRefGoogle Scholar
  27. 27.
    Cheong JY, Cho SW, Oh B, Kimm K, Lee KM, Shin SJ, et al. Association of interleukin-18 gene polymorphisms with hepatitis B virus clearance. Dig Dis Sci. 2010;55:1113–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Zhang PA, Wu JM, Li Y, Yang XS. Association of polymorphisms of interleukin-18 gene promoter region with chronic hepatitis B in Chinese Han population. World J Gastroenterol. 2005;11:1594–8.PubMedGoogle Scholar
  29. 29.
    Migita K, Sawakami-Kobayashi K, Maeda Y, Nakao K, Kondoh S, Sugiura M, et al. Interleukin-18 promoter polymorphisms and the disease progression of hepatitis B virus-related liver disease. Transl Res. 2009;153:91–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Chen Q, Liao WJ, He SQ, Yuan SG, Qin LL, Yu YQ, et al. The correlation between single nucleotide polymorphism of interleukin-18 gene promoter and genetic susceptibility to hepatocellular carcinoma. Immunol J. 2012;28:1051–5 [Article in Chinese].Google Scholar
  31. 31.
    Li N, Gao YF, Zhang TC, Chen P, Li X, Su F. Relationship between interleukin 18 polymorphisms and susceptibility to chronic hepatitis B virus infection. World J Hepatol. 2012;4:105–9.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Gao JM, Zou YL, Dong H, Tang H, Xu Y, Yan XM. Relationship between HBV infection and polymorphism of IL-18 promoter gene among three minority populations in Yunnan province. Chin J Clin. 2010;4:1525–31 [Article in Chinese].Google Scholar
  33. 33.
    Chen J, Wang L, Li Y, Cai B, Fu Y, Liao Y, et al. Association analysis between SNPs in IL-28B gene and the progress of hepatitis B infection in Han Chinese. PLoS One. 2012;7(12):e50787.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Ren S, Lu J, Du X, Huang Y, Ma L, Huo H, et al. Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma. Cancer Immunol Immunother. 2012;61:1433–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Martin MP, Qi Y, Goedert JJ, Hussain SK, Kirk GD, Hoots WK, et al. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis. 2010;202:1749–53.PubMedCrossRefGoogle Scholar
  36. 36.
    Martín-Carbonero L, Rallón NI, Benito JM, Poveda E, González-Lahoz J, Soriano V. Does interleukin-28B single nucleotide polymorphisms influence the natural history of hepatitis B? AIDS Res Hum Retroviruses. 2012;28:1262–4.PubMedCrossRefGoogle Scholar
  37. 37.
    Wang Y, Zhang HH, Chen YH, Xie XW, Liao WJ, Qin LL, et al. Correlation between interleukin-28B genetic polymorphisms and primary hepatocellular carcinoma. Zhonghua Yu Fang Yi Xue Za Zhi. 2012;46:527–32 [Article in Chinese].PubMedGoogle Scholar
  38. 38.
    Jiao XL, Gao YT, Jing L, Liu T, Shi WX, Guo H, et al. Studies on the relationship between polymorphism of IL-28B rs8099917 and the outcome of HBV infection. Zhonghua Liu Xing Bing Xue Za Zhi. 2011;32:1143–7 [Article in Chinese].PubMedGoogle Scholar
  39. 39.
    Fabris C, Falleti E, Cussigh A, Bitetto D, Fontanini E, Bignulin S, et al. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol. 2011;54:716–22.PubMedCrossRefGoogle Scholar
  40. 40.
    Dunford L, Carr MJ, Dean J, Nguyen LT, Ta Thi TH, Nguyen BT, et al. A multicentre molecular analysis of hepatitis B and blood-borne virus coinfections in Viet Nam. PLoS One. 2012;7:e39027.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Holmes JA, Nguyen T, Ratnam D, Heerasing NM, Tehan JV, Bonanzinga S, et al. IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α. J Gastroenterol Hepatol. 2013;28:861–6.PubMedCrossRefGoogle Scholar
  42. 42.
    Lee IC, Lin CH, Huang YH, Huo TI, Su CW, Hou MC, et al. IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B. PLoS One. 2013;8:e58071.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Sonneveld MJ, Wong VW, Wotman AM, Wong GLH, Buster EHCJ, Hansen BE, et al. Polymorphisms at rs12979860 and rs12980275 near IL28B predict serological response to (Peg)-interferon in HBeAg-positive chronic hepatitis B. J Hepatol. 2011;54:S32.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Pu Xia
    • 1
  • Mo Zhou
    • 2
  • Dao Song Dong
    • 3
  • Ya-Nan Xing
    • 4
  • Yang Bai
    • 5
  1. 1.Department of Biochemistry and Molecular Biology, School of Basic Medical ScienceChina Medical UniversityShenyangPeople’s Republic of China
  2. 2.Medical Laboratory Technology CenterChina Medical UniversityShenyangPeople’s Republic of China
  3. 3.Department of Anaesthesiology, First Affiliated HospitalChina Medical UniversityShenyangPeople’s Republic of China
  4. 4.Department of Surgical Oncology, First Affiliated HospitalChina Medical UniversityShenyangPeople’s Republic of China
  5. 5.Department of Clinical Pharmacology, College of PharmacyChina Medical UniversityShenyangPeople’s Republic of China

Personalised recommendations